İdiyopatik Pulmoner Fibrozis Tanıdan Tedaviye Güncel Yaklaşım

Aburto M, Perez-Izquierdo J, Agirre U, et al. Complications and hospital admission in the following 90 days after lung cryobiopsy performed in interstitial lung disease. Respir Med. 2020;165:105934.

Achkar M, Jamal O, Chaaban T. Post-COVID lung diseases. Ann Thorac Med. 2022;17:137–144.

Agarwal S, Richardson B, Krishnan V, et al. Interstitial lung disease and sleep: what is known? Sleep Med. 2009;10(9):947–951.

Akagi T, Matsumoto T, Harada T, et al. Coexistent emphysema delays the decrease of vital capacity in idiopathic pulmonary fibrosis. Respir Med. 2009;103(8):1209-1215.

Akhtar AA, Ali MA, Smith R. Depression in patients with idiopathic pulmonary fibrosis. Chron Respir Dis. 2013;10:127–133.

Akira M, Kozuka T, Yamamoto S, Sakatani M. Computed tomography findings in acute exacerbation of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2008;178(4):372–378.

Albera C, Costabel U, Fagan EA, et al. Efficacy of pirfenidone in patients with idiopathic pulmonary fibrosis with more preserved lung function. Eur Respir J. 2016;48(3):843–851.

Alder JK, Chen JJ, Lancaster L, et al. Short telomeres are a risk factor for idiopathic pulmonary fibrosis. Proc Natl Acad Sci U S A. 2008;105(35):13051–13056.

Alfaro TM, Cordeiro CR. Comorbidity in idiopathic pulmonary fibrosis - what can biomarkers tell us? Ther Adv Respir Dis. 2020;14:1-10.

Alkukhun L, Wang XF, Ahmed MK, et al. Non-invasive screening for pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med. 2016;117:65–72.

Allaix ME, Fisichella PM, Noth I, et al. Idiopathic pulmonary fibrosis and gastroesophageal reflux: implications for treatment. J Gastrointest Surg. 2014;18(1):100–105.

Allen S, Raut S, Woollard J, et al. Low dose diamorphine reduces breathlessness without causing a fall in oxygen saturation in elderly patients with end-stage idiopathic pulmonary fibrosis. Palliat Med. 2005;19(2):128–130.

Alvarez D, Cardenes N, Sellares J, et al. IPF lung fibroblasts have a senescent phenotype. Am J Physiol Lung Cell Mol Physiol. 2017;313(6):L1164–1173.

American Thoracic Society (ATS). European Respiratory Society idiopathic pulmonary fibrosis: diagnosis and treatment, international consensus statement. Am J Respir Crit Care Med. 2000;161:646–664.

American Thoracic Society, European Respiratory Society. International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2002;165(2):277–304.

American Thoracic Society. ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med. 2002;166(1):111–117.

Anan K, Kataoka Y, Ichikado K, et al. Early corticosteroid dose tapering in patients with acute exacerbation of idiopathic pulmonary fibrosis. Respir Res. 2022;23(1):291.

Andrade BS, Siqueira S, Soares WR, Souza WS, Freitas AD, Villar-Delfino PH, et al. Long-COVID and post-COVID health complications: An up-to-date review on clinical conditions and their possible molecular mechanisms. Viruses. 2021;13:700.

Antoniou KM, Tomassetti S, Tsitoura E, et al. Idiopathic pulmonary fibrosis and lung cancer: a clinical and pathogenesis update. Curr Opin Pulm Med. 2015;21(6):626–633.

Antoniou KM, Tomassetti S, Tsitoura E, Vancheri C. Idiopathic pulmonary fibrosis and lung cancer: a clinical and pathogenesis update. Curr Opin Pulm Med. 2015;21:626–633.

Arcasoy SM, Christie JD, Ferrari VA, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med. 2003;167(5):735–740.

Arizono S, Furukawa T, Taniguchi H, et al. Supplemental oxygen improves exercise capacity in IPF patients with exertional desaturation. Respirology. 2020;25(11):1152–1159.

Atkins CP, Loke YK, Wilson AM. Outcomes in idiopathic pulmonary fibrosis: a meta-analysis from placebo-controlled trials. Respir Med. 2014;108(2):376–387.

Aubry MC, Myers JL, Douglas WW, et al. Primary pulmonary carcinoma in patients with idiopathic pulmonary fibrosis. Mayo Clin Proc. 2002;77(8):763–770.

Aul R, Gates J, Draper A, Das KM, Shankar S, El-Ghazawi A, et al. Complications after discharge with COVID-19 infection and risk factors associated with development of post-COVID pulmonary fibrosis. Respir Med. 2020;8(8):807–815.

Bajwah S, Davies JM, Tanash H, et al. Safety of benzodiazepines and opioids in interstitial lung disease: a national prospective study. Eur Respir J. 2018;52(6):1801278.

Balestro E, Calabrese F, Turato G, et al. Immune inflammation and disease progression in idiopathic pulmonary fibrosis. PLoS One. 2016;11(5):e0154516.

Bartczak K, Białas AJ, et al. More Than a Genetic Code: Epigenetics of Lung Fibrosis. Mol Diagn Ther. 2020;24:665–681.

Baumgartner KB, Samet JM, Coultas DB, et al. Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Am J Epidemiol. 2000;152:307–315.

Beauchamp MK, Janaudis-Ferreira T, Wald J, Goldstein RS, Brooks D. Canadian Thoracic Society position statement on rehabilitation for COVID-19 and implications for pulmonary rehabilitation. Can J Respir Crit Care Sleep Med. 2022;6:9–13.

Behr J, Prasse A, Kreuter M, et al; RELIEF Investigators. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9:476–486.

Behr J, Ryu JH. Pulmonary hypertension in interstitial lung disease. Eur Respir J. 2008;31(6):1357–1367.

Behr J, Ryu JH. Pulmonary hypertension in interstitial lung disease. Eur Respir J. 2008;31:1357-1367.

Behr J, Ryu JH. Pulmonary hypertension in interstitial lung disease. Eur Respir J. 2008;31(6):1357–1362.

Best AC, Meng J, Lynch AM, et al. Idiopathic pulmonary fibrosis: physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality. Radiology. 2008;246(3):935–940.

Betensley A, Sharif R, Karamichos D. A systematic review of the role of dysfunctional wound healing in the pathogenesis and treatment of idiopathic pulmonary fibrosis. J Clin Med. 2017;6:2–19.

Biondini D, Balestro E, Sverzellati N, et al. Acute exacerbations of idiopathic pulmonary fibrosis (AE-IPF): an overview of current and future therapeutic strategies. Expert Rev Respir Med. 2020;14(4):405–414.

Birring SS, Wijsenbeek MS, Agrawal S, et al. A novel formulation of inhaled sodium cromoglicate (PA101) in idiopathic pulmonary fibrosis and chronic cough: a randomized, double-blind, proof-of-concept, phase 2 trial. Lancet Respir Med. 2017;5(10):806–815.

Bjoraker JA, Ryu JH, Edwin MK, et al. Prognostic significance of histopathologic subsets in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1998;157(1):199–203.

Blivet S, Philit F, Sab JM, et al. Outcome of patients with idiopathic pulmonary fibrosis admitted to the ICU for respiratory failure. Chest. 2001;120:209–212.

Boonpheng B, Ungprasert P. Risk of venous thromboembolism in patients with idiopathic pulmonary fibrosis: A systematic review and meta-analysis. Sarcoidosis Vasc Diffuse Lung Dis. 2018;35:109–114.

Bosi M, Milioli G, Parrino L, et al. Quality of life in idiopathic pulmonary fibrosis: the impact of sleep disordered breathing. Respir Med. 2019;147:51–57.

Bouros D, Hatzakis K, Labrakis H, Zeibecoglou K. Association of malignancy with diseases causing interstitial pulmonary changes. Chest. 2002;121:1278–1289.

Bräunlich J, Beyer D, Mai D, et al. Effects of nasal high flow on ventilation in volunteers, COPD and idiopathic pulmonary fibrosis patients. Respiration. 2013;85(4):319–325.

Brigham E, O’Toole J, Kim SY, Friedman E, Friedman C, Bhasin R, et al. The Johns Hopkins Post-Acute COVID-19 Team (PACT): A multidisciplinary, collaborative, ambulatory framework supporting COVID-19 survivors. Am J Med. 2021;134:462–467.

Brix N, Rasmussen F, Poletti V, Bendstrup E. Eosinophil alveolitis in two patients with idiopathic pulmonary fibrosis. Respir Med Case Rep. 2016;19:61–64.

Brownell R, Moua T, Henry TS, et al. The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia. Thorax. 2017;72(5):424.

Buendía-Roldán I, Mejía M, Navarro C, Selman M. Idiopathic pulmonary fibrosis: clinical behavior and aging associated comorbidities. Respir Med. 2017;129:46–52.

Buttery S, PhiLIP KEJ, Williams P, Fallas A, West B, Cumella A, et al. Patients' symptoms and experience following COVID-19: Results from UK-wide survey. BMJ Open Respir Res. 2021;8:e001075.

Caminati A, Cassandro R, Torre O, Harari S. Severe idiopathic pulmonary fibrosis: what can be done? Eur Respir Rev. 2017;26(145):170047.

Casoni GL, Tomassetti S, Cavazza A, et al. Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases. PLoS One. 2014;9:e86716.

Centers for Disease Control and Prevention (CDC). Science brief: Long COVID or post-COVID conditions [Internet]. Atlanta (GA): CDC; [cited 2025 Aug 1]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-science.html

Chung JH, Lynch DA. The value of a multidisciplinary approach to the diagnosis of usual interstitial pneumonitis and idiopathic pulmonary fibrosis: radiology, pathology, and clinical correlation. AJR Am J Roentgenol. 2016;206:463.

Clark M, Cooper B, Singh S, et al. A survey of nocturnal hypoxaemia and health-related quality of life in patients with cryptogenic fibrosing alveolitis. Thorax. 2001;56:482–486.

Collard HR, Anstrom KJ, Schwarz MI, et al. Sildenafil improves walk distance in idiopathic pulmonary fibrosis. Chest. 2007;131(3):897–899.

Collard HR, Chen SY, Yeh WS, et al. Health care utilization and costs in idiopathic pulmonary fibrosis in United States Medicare beneficiaries aged 65 years and older. Ann Am Thorac Soc. 2015;12:981–987.

Collard HR, King TE Jr, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2003;168(5):538–542.

Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2007;176(7):636–643.

Collard HR, Richeldi L, Kim DS, et al. Acute exacerbations in the INPULSIS trials of nintedanib in idiopathic pulmonary fibrosis. Eur Respir J. 2017;49(5):1601339.

Collard HR, Ryerson CJ, Corte TJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med. 2016;194(3):265–275.

Collard HR, Tino G, Noble PW, et al. Patient experiences with pulmonary fibrosis. Respir Med. 2007;101:1350–1354.

Condoluci C, Inchingolo R, Mastrobattista A, et al. IPF: treatment and prevention of pulmonary exacerbations. In: Burgel PR, Contoli M, López-Campos JL, eds. Acute Exacerbations of Pulmonary Diseases. Sheffield: European Respiratory Society; 2017:199–223.

Conte E, Gili E, Fagone E, et al. Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts. Eur J Pharm Sci. 2014;58:13-19.

Corte TJ, Wort SJ, Talbot S, et al. Elevated nocturnal desaturation index predicts mortality in interstitial lung disease. Sarcoidosis Vasc Diffuse Lung Dis. 2012;29:41–50.

Costabel U, Albera C, Glassberg MK, et al. Effect of pirfenidone in patients with more advanced idiopathic pulmonary fibrosis. Respir Res. 2019;20(1):55.

Costabel U, Albera C, Lancaster LH, et al. An open-label study of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis (RECAP). Respiration. 2017;94(5):408-415.

Costabel U, Behr J, Crestani B, et al. Anti-acid therapy in idiopathic pulmonary fibrosis: insights from the INPULSIS® trials. Respir Res. 2018;19:167.

Cottin V, Le Pavec J, Prevot G, et al. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J. 2010;35:105–111.

Cottin V, Nunes H, Brillet PY, Delaval P, Devouassoux G, Tillie-Leblond I, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005;26(4):586–593.

Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J. 2005;26:586–593.

Cottin V, Tomassetti S, Valenzuela C, et al. Integrating clinical probability into the diagnostic approach to idiopathic pulmonary fibrosis: an international working group perspective. Am J Respir Crit Care Med. 2022;206:247–255.

Cottin V, Valenzuela C. Diagnostic approach of fibrosing interstitial lung diseases of unknown origin. Presse Med. 2020;49(2):104021.

Cottin V, Wollin L, Fischer A, Quaresma M, Stowasser S, Harari S. Fibrosing interstitial lung diseases: knowns and unknowns. Eur Respir J. 2016;47(2):657–666.

Coultas DB, Zumwalt RE, Black WC, et al. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med. 1994;150(4):967-972.

Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med. 1994;150:967–972.

Crestani B, Huggins JT, Kaye M, et al. Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON. Lancet Respir Med. 2019;7(1):60-68

Crystal RG, Fulmer JD, Roberts WC, et al. Idiopathic pulmonary fibrosis. Clinical, histologic, radiographic, physiologic, scintigraphic, cytologic, and biochemical aspects. Ann Intern Med. 1976;85(6):769–788.

Cuerpo S, Moisés J, Hernández-González F, et al. Acute exacerbations of idiopathic pulmonary fibrosis: does clinical stratification or steroid treatment matter? Chron Respir Dis. 2019;16:1479973119869334.

Culebras M, Loor K, Sansano I, Martinez E, Aguilar R, Rodó C, et al. Histological findings in transbronchial cryobiopsies obtained from patients after COVID-19. Chest. 2022;161:647–650.

Daniels CE, Jett JR. Does interstitial lung disease predispose to lung cancer? Curr Opin Pulm Med. 2005;11(5):431–437.

Daniels CE, Yi ES, Ryu JH. Autopsy findings in 42 consecutive patients with idiopathic pulmonary fibrosis. Eur Respir J. 2008;32(1):170–174.

Ding J, Chen Z, Feng K. Procalcitonin-guided antibiotic use in acute exacerbations of idiopathic pulmonary fibrosis. Int J Med Sci. 2013;10(7):903–907.

Distler O, Highland KB, Gahlemann M, et al; SENSCIS Trial Investigators. Nintedanib for systemic sclerosis-associated interstitial lung disease. N Engl J Med. 2019;380(26):2518–2528.

Dowman L, Hill CJ, May A, et al. Pulmonary rehabilitation for interstitial lung disease. Cochrane Database Syst Rev. 2021;2021(2):CD006322.

du Bois RM, Weycker D, Albera C, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(4):459.

Eaton T, Young P, Milne D, Wells AU. Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med. 2005;171(10):1150-1157.

Echeverria-Esnal D, Martin-Ontiyuelo C, Navarrete-Rouco ME, De-Antonio C, Ferrández O, Horcajada JP, et al. Azithromycin in the treatment of COVID-19: A review. Expert Rev Anti Infect Ther. 2021;19:147–163.

Ekström M, Gustafson T, Boman K, et al. Effects of smoking, gender and occupational exposure on the risk of severe pulmonary fibrosis: a population-based case-control study. BMJ Open. 2014;4(1):e004018.

Enomoto N, Mikamo M, Oyama Y, et al. Treatment of acute exacerbation of idiopathic pulmonary fibrosis with direct hemoperfusion using a polymyxin B-immobilized fiber column improves survival. BMC Pulm Med. 2015;15:15.

Enomoto N, Suda T, Kato M, et al. Quantitative analysis of fibroblastic foci in usual interstitial pneumonia. Chest. 2006;130(1):22–29.

Enomoto T, Usuki J, Azuma A, et al. Diabetes mellitus may increase risk for idiopathic pulmonary fibrosis. Chest. 2003;123:2007–2011.

Farghaly S, Badedi M, Ibrahim R, Alnami A, Gohal G, Balawi M, et al. Clinical characteristics and outcomes of post-COVID-19 pulmonary fibrosis: A case-control study. Medicine (Baltimore). 2022;101(3):e28639.

Fell CD, Liu LX, Motika C, et al. The prognostic value of cardiopulmonary exercise testing in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179(5):402-407.

Fell CD, Martinez FJ, Liu LX, et al. Clinical predictors of a diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2010;181(8):832-837.

Fernandez IE, Eickelberg O. New cellular and molecular mechanisms of lung injury and fibrosis in idiopathic pulmonary fibrosis. Lancet. 2021;380:680–688.

Fernandez Perez ER, Daniels CE, Schroeder DR, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest. 2010;137:129–137.

Fernández Pérez ER, Daniels CE, Schroeder DR, et al. Incidence, prevalence, and clinical course of idiopathic pulmonary fibrosis: a population-based study. Chest. 2010;137(1):129–137.

Fernandez-de-Las-Penas C, Palacios-Cena D, Gomez-Mayordomo V, Cuadrado ML, Florencio LL. Fatigue and dyspnoea as main persistent post-COVID-19 symptoms in previously hospitalized patients: Related functional limitations and disability. Respiration. 2022;101:132–41.

Ferreira A, Garvey C, Connors GL, et al. Pulmonary rehabilitation in interstitial lung disease: benefits and predictors of response. Chest. 2009;135:442–447.

Finnerty JP, Ponnuswamy A, Dutta P, et al. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: a systematic review and meta-analysis. BMC Pulm Med. 2021;21(1):411.

Fischer A, Antoniou KM, Brown KK, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015;46(4):976–987.

Fischer A, Antoniou KM, Brown KK, et al. An official European Respiratory Society/American Thoracic Society research statement: interstitial pneumonia with autoimmune features. Eur Respir J. 2015;46(4):976–987. doi:10.1183/13993003.00150-2015

Fisher M, Nathan SD, Hill C, et al. Predicting life expectancy for pirfenidone in idiopathic pulmonary fibrosis. J Manag Care Spec Pharm. 2017;23(3-b):S17-S24.

Fisher MR, Forfia PR, Chamera E, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009;179(7):615–621.

Flaherty KR, Andrei AC, Murray S, et al. Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med. 2006;174(7):803–809.

Flaherty KR, Colby TV, Travis WD, et al. Fibroblastic foci in usual interstitial pneumonia: idiopathic versus collagen vascular disease. Am J Respir Crit Care Med. 2003;167(10):1410–1415.

Flaherty KR, King TE Jr, Raghu G, et al. Idiopathic interstitial pneumonia: what is the effect of a multidisciplinary approach to diagnosis? Am J Respir Crit Care Med. 2004;170(8):904-910.

Flaherty KR, Thwaite EL, Kazerooni EA, et al. Radiological versus histological diagnosis in UIP and NSIP: survival implications. Thorax. 2003;58(2):143–148.

Flaherty KR, Wells AU, Cottin V, et al; INBUILD Trial Investigators. Nintedanib in progressive fibrosing interstitial lung diseases. N Engl J Med. 2019;381:1718–1727.

Frank RC, Hicks S, Duck AM, et al. Ambulatory oxygen in idiopathic pulmonary fibrosis: of what benefit? Eur Respir J. 2012;40(1):269–270.

Fujimoto K, Taniguchi H, Johkoh T, et al. Acute exacerbation of idiopathic pulmonary fibrosis: high-resolution CT scores predict mortality. Eur Radiol. 2012;22(1):83–92.

Fukihara J, Kondoh Y, Brown KK, et al. Probable usual interstitial pneumonia pattern on chest CT: is it sufficient for a diagnosis of idiopathic pulmonary fibrosis? Eur Respir J. 2020;55:1802465.

Fulton BG, Ryerson CJ. Managing comorbidities in idiopathic pulmonary fibrosis. Int J Gen Med. 2015;8:309–318.

Funke-Chambour M, Azzola A, Adler D, et al. Idiopathic pulmonary fibrosis in Switzerland: diagnosis and treatment position paper of the Swiss Working Group for Interstitial and Rare Lung Diseases of the Swiss Respiratory Society. Respiration. 2017;93:363–378.

Funke-Chambour M, Azzola A, Adler D, et al. Idiopathic pulmonary fibrosis in Switzerland: diagnosis and treatment position paper of the Swiss Working Group for Interstitial and Rare Lung Diseases of the Swiss Respiratory Society. Respiration. 2017;93:363–378.

Funke-Chambour M, Bridevaux PO, Clarenbach CF, Soccal PM, Nicod L. Swiss recommendations for the follow-up and treatment of pulmonary long COVID. Respiration. 2021;100:826–841.

Gaensler EA, Moister VB, Hamm J. Open-lung biopsy in diffuse pulmonary disease. N Engl J Med. 1964;270:1319–1331.

Gao F, Hobson AR, Shang ZM, et al. The prevalence of gastro-esophageal reflux disease and esophageal dysmotility in Chinese patients with idiopathic pulmonary fibrosis. BMC Gastroenterol. 2015;15:26.

Garcia CK, Raghu G. Inherited interstitial lung disease. Clin Chest Med. 2004;25(3):421–433.

Gaunaurd IA, Gomez-Marin OW, Ramos CF, et al. Physical activity and quality of life improvements of patients with idiopathic pulmonary fibrosis completing a pulmonary rehabilitation program. Respir Care. 2014;59(12):1872–1879.

Gay SE, Kazerooni EA, Toews GB, et al. Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med. 1998;157(4 Pt 1):1063–1072.

George PM, Barratt SL, Condliffe R, Desai SR, Devaraj A, Forrest I, et al. Respiratory follow-up of patients with COVID-19 pneumonia. Thorax. 2020;75:1009–1016.

Ghazipura MHM, Mammen MJ, Herman DD, et al. Nintedanib in progressive pulmonary fibrosis: a systematic review and meta-analysis. Ann Am Thorac Soc. 2022;19(6):1040–1049.

Glass DS, Grossfeld D, Renna HA, et al. Idiopathic Pulmonary Fibrosis: Molecular Mechanisms and Potential Treatment Approaches. Respir Investig. 2020;58:320–335.

Gotway MB, Freemer MM, King TE Jr. Challenges in pulmonary fibrosis. 1: Use of high-resolution CT scanning of the lung for the evaluation of patients with idiopathic interstitial pneumonias. Thorax. 2007;62(6):546–553.

Gross P. The concept of the Hamman-Rich syndrome. A critique. Am Rev Respir Dis. 1962;85:828–832.

Gruden JF, Panse PM, Gotway MB, et al. Diagnosis of usual interstitial pneumonitis in the absence of honeycombing: evaluation of specific CT criteria with clinical follow-up in 38 patients. AJR Am J Roentgenol. 2016;206(3):472.

Gruden JF, Panse PM, Leslie KO, et al. UIP diagnosed at surgical lung biopsy, 2000-2009: YÇBT patterns and proposed diagnostic approach. AJR Am J Roentgenol. 2013;200(6):W458-467.

Guiot J, Moermans C, Henket M, et al. Blood biomarkers in idiopathic pulmonary fibrosis. Lung. 2017;195:273–280

Hallstrand TS, Boitano LJ, Johnson WC, et al. The timed walk test as a measure of severity and survival in idiopathic pulmonary fibrosis. Eur Respir J. 2005;25(1):96-103.

Hama Amin BJ, Kakamad FH, Ahmed GS, Abdulla BA, Mohammed SH, Rasul SF, et al. Post-COVID-19 pulmonary fibrosis: A meta-analysis study. Ann Med Surg (Lond). 2022;77:103590.

Hambley N, Shimbori C, Kolb M. Molecular classification of idiopathic pulmonary fibrosis: personalized medicine, genetics and biomarkers. Respirology. 2015;20:1010–1022.

Hambly N, Cox G, Kolb M. Acute exacerbations of idiopathic pulmonary fibrosis: tough to define; tougher to manage. Eur Respir J. 2017;49(3):1700811.

Hamman L, Rich AR. Acute diffuse interstitial fibrosis of the lungs. Bull Johns Hopkins Hosp. 1944;74:177–212.

Han MK, Murray S, Fell CD, et al. Sex differences in physiological progression of idiopathic pulmonary fibrosis. Eur Respir J. 2008;31(6):1183–1188.

Han MLK, Zhou Y, Murray S, et al. Lung microbiome and disease progression in idiopathic pulmonary fibrosis: an analysis of the COMET study. Lancet Respir Med. 2014;2:548–556.

Hanak V, Ryu JH, de Carvalho E, et al. Profusion of fibroblast foci in patients with idiopathic pulmonary fibrosis does not predict outcome. Respir Med. 2008;102(6):852–856.

Harari S, Elia D, Humbert M. Pulmonary hypertension in parenchymal lung diseases: any future for new therapies? Chest. 2018;153(1):217–223.

Hatabu H, Hunninghake GM, Lynch DA. Interstitial lung abnormality: recognition and perspectives. Radiology. 2019;291:1–3.

Hernandez-Rodriguez NA, Cambrey AD, Chambers RC, et al. Role of thrombin in pulmonary fibrosis. Lancet. 1995;346:1071–1073.

Hetzel J, Maldonado F, Ravaglia C, et al. Transbronchial cryobiopsies for the diagnosis of diffuse parenchymal lung diseases: expert statement from the cryobiopsy working group on safety and utility and a call for standardization of the procedure. Respiration. 2018;95:188–200.

Heukels P, Moor CC, von der Thüsen JH, et al. Inflammation and Immunity in IPF Pathogenesis and Treatment. Respir Med. 2019;147:79–91.

Hilberg O, Bendstrup E, Lokke A, et al. Co-morbidity and mortality among patients with interstitial lung diseases: a population-based study. Respirology. 2018;23(6):606–612.

Hirano C, Ohshimo S, Horimasu Y, et al. Baseline high-resolution CT findings predict acute exacerbation of idiopathic pulmonary fibrosis: German and Japanese cohort study. J Clin Med. 2019;8(12):2069.

Hisata S, Bando M, Homma S, et al. Safety and tolerability of combination therapy with pirfenidone and nintedanib for idiopathic pulmonary fibrosis: a multicenter retrospective observational study in Japan. Respir Investig. 2021;59(6):819-826.

Hodnett PA, Naidich DP. Fibrosing interstitial lung disease. A practical high-resolution computed tomography-based approach to diagnosis and management and a review of the literature. Am J Respir Crit Care Med. 2013;188(2):141-149.

Hoeper MM, Behr J, Held M, et al. Pulmonary hypertension in patients with chronic fibrosing idiopathic interstitial pneumonias. PLoS One. 2015;10(12):e0141911.

Holland AE, Fiore JF Jr, Bell EC, et al. Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease. Respirology. 2014;19:1215–1221.

Horton MR, Santopietro V, Mathew L, et al. Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med. 2012;157(6):398–406.

Hoyer N, Prior TS, Bendstrup E, Shaker SB. Diagnostic delay in IPF impacts progression-free survival, quality of life and hospitalisation rates. BMJ Open Respir Res. 2022;9:e001276.

Hu ZJ, Xu J, Yin JM, Li L, Hou W, Zhang LL, et al. Lower circulating interferon-gamma is a risk factor for lung fibrosis in COVID-19 patients. Front Immunol. 2020;11:585647.

Huang W, Wu Q, Chen Z, Xiong Z, Wang L, Wu J, et al. The potential indicators for pulmonary fibrosis in survivors of severe COVID-19. J Infect. 2021;82:e5–e7.

Huang Y, Ma SF, Espindola MS, et al. Microbes are associated with host innate immune response in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2017;196:208–219.

Hubbard R, Venn A, Lewis S, et al. Lung cancer and cryptogenic fibrosing alveolitis: a population-based cohort study. Am J Respir Crit Care Med. 2000;161:5-8.

Hubbard RB, Smith C, Le Jeune I, et al. The association between idiopathic pulmonary fibrosis and vascular disease: a population-based study. Am J Respir Crit Care Med. 2008;178:1257–1261.

Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43:3618-3731.

Hunninghake GM, Quesada-Arias LD, Carmichael NE, et al. Interstitial lung disease in relatives of patients with pulmonary fibrosis. Am J Respir Crit Care Med. 2020;201(10):1240–1248.

Hutchinson JP, Fogarty AW, McKeever TM, et al. In-hospital mortality after surgical lung biopsy for interstitial lung disease in the United States. Am J Respir Crit Care Med. 2016;193:1161–1167.

Hutchinson JP, McKeever TM, Fogarty AW, et al. Increasing global mortality from idiopathic pulmonary fibrosis in the twenty-first century. Ann Am Thorac Soc. 2014;11:1176–1185.

Idiopathic Pulmonary Fibrosis Clinical Research Network, Raghu G, et al. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012;366:1968-1977.

Isshiki T, Sakamoto S, Yamasaki A, et al. Incidence of acute exacerbation of idiopathic pulmonary fibrosis in patients receiving antifibrotic agents: real-world experience. Respir Med. 2021;187:106551

Iwanami Y, Ebihara K, Nakao K, et al. Benefits of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis receiving antifibrotic drug treatment. J Clin Med. 2022;11(18):5336.

Iwata T, Yoshino I, Yoshida S, et al. A phase II trial evaluating the efficacy and safety of perioperative pirfenidone for prevention of acute exacerbation of idiopathic pulmonary fibrosis in lung cancer patients undergoing pulmonary resection: West Japan Oncology Group 6711L (PEOPLE Study). Respir Res. 2016;17(1):90.

Jackson RM, Gomez-Marin OW, Ramos CF, et al. Exercise limitation in IPF patients: a randomized trial of pulmonary rehabilitation. Lung. 2014;192(3):367–376.

JafariNezhad A, YektaKooshali MH. Lung cancer in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. PLoS One. 2018;13(8):e0202360.

Jakubec P, Fiserova K, Genzor S, Kolaf M. Pulmonary complications after COVID-19. Life (Basel). 2022;12:357.

Jankowich MD, Rounds SI. Combined pulmonary fibrosis and emphysema syndrome: a review. Chest. 2012;141(1):222–231.

Jankowich MD, Rounds SIS. Combined pulmonary fibrosis and emphysema syndrome: a review. Chest. 2012;141(1):222-231.

Johannson KA, Pendharkar SR, Mathison K, et al. Supplemental oxygen in interstitial lung disease: an art in need of science. Ann Am Thorac Soc. 2017;14(9):1373–1377.

John AE, Joseph C, Jenkins G, Tatler AL. COVID-19 and pulmonary fibrosis: A potential role for lung epithelial cells and fibroblasts. Immunol Rev. 2021;302:228–240.

Juarez MM, Chan AL, Norris AG, et al. Acute exacerbation of idiopathic pulmonary fibrosis—a review of current and novel pharmacotherapies. J Thorac Dis. 2015;7(3):499–519.

Justet A, Laurent-Bellue A, Thabut G, et al. [18F]FDG PET/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis. Respir Res. 2017;18(1):74.

Kapnadak SG, Raghu G. Lung transplantation for interstitial lung disease. Eur Respir Rev. 2021;30(161):210017.

Kato E, Takayanagi N, Takaku Y, et al. Incidence and predictive factors of lung cancer in patients with idiopathic pulmonary fibrosis. ERJ Open Res. 2018;4(1):2011–2016.

Kato M, Yamada T, Kataoka S, et al. Prognostic differences among patients with idiopathic interstitial pneumonias with acute exacerbation of varying pathogenesis: a retrospective study. Respir Res. 2019;20(1):287.

Katzenstein AL, Mukhopadhyay S, Myers JL. Diagnosis of usual interstitial pneumonia and distinction from other fibrosing interstitial lung diseases. Hum Pathol. 2008;39(9):1275–1294.

Katzenstein AL, Myers JL. Idiopathic pulmonary fibrosis: clinical relevance of pathologic classification. Am J Respir Crit Care Med. 1998;157(4 Pt 1):1301–1315.

Katzenstein AL, Myers JL. Nonspecific interstitial pneumonia and the other idiopathic interstitial pneumonias: classification and diagnostic criteria. Am J Surg Pathol. 2000;24(1):1–3.

Katzenstein AL. Pathogenesis of “fibrosis” in interstitial pneumonia: an electron microscopic study. Hum Pathol. 1985;16(10):1015–1024.

Katzenstein A-LA, Askin FB, Livolsi VA. Katzenstein and Askin’s Surgical Pathology of Non-neoplastic Lung Disease. 4th ed. Philadelphia, PA: Saunders/Elsevier; 2006.

Katzenstein A-LA, Mukhopadhyay S, Myers JL. Diagnosis of usual interstitial pneumonia and distinction from other fibrosing interstitial lung diseases. Hum Pathol. 2008;39(9):1275–1294.

Kaur A, Mathai SK, Schwartz DA. Genetics in idiopathic pulmonary fibrosis pathogenesis, prognosis, and treatment. Front Med (Lausanne). 2017;4:154.

Kebbe J, Abdo T. Interstitial lung disease: the diagnostic role of bronchoscopy. J Thorac Dis. 2017;9(10):996–1000.

Kheir F, Alkhatib A, Berry GJ, et al. Using bronchoscopic lung cryobiopsy and a genomic classifier in the multidisciplinary diagnosis of diffuse interstitial lung diseases. Chest. 2020;158:2015-2025.

Kheir F, Uribe Becerra JP, Bissell B, et al. Transbronchial lung cryobiopsy in patients with interstitial lung disease: a systematic review. Ann Am Thorac Soc. 2022;19(7):1193-1202.

Kheir F, Uribe Becerra JP, et al. Use of a genomic classifier in patients with interstitial lung disease: a systematic review. Ann Am Thorac Soc. 2022;19(5):827-832.

Kim DS, Collard HR, King TE Jr. Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc. 2006;3(4):285–292.

Kim HJ, Perlman D, Tomic R. Natural history of idiopathic pulmonary fibrosis. Respir Med. 2015;109(6):661-670.

Kim SY, Diggans J, Pankratz D, et al. Classification of usual interstitial pneumonia in patients with interstitial lung disease: assessment of a machine learning approach using high-dimensional transcriptional data. Lancet Respir Med. 2015;3:473–482.

Kim YJ, Park JW, Kyung SY, et al. Clinical characteristics of idiopathic pulmonary fibrosis patients with diabetes mellitus: the national survey in Korea from 2003 to 2007. J Korean Med Sci. 2012;27:756–760.

Kimura M, Taniguchi H, Kondoh Y, et al. Pulmonary hypertension as a prognostic indicator at the initial evaluation in idiopathic pulmonary fibrosis. Respiration. 2013;85:456-463.

Kinder BW, Brown KK, McCormack FX, et al. Serum surfactant protein-A is a strong predictor of early mortality in idiopathic pulmonary fibrosis. Chest. 2009;135(6):1557–1563.

Kinder BW, Brown KK, Schwarz MI, et al. Basal BAL neutrophilia predicts early mortality in idiopathic pulmonary fibrosis. Chest. 2008;133(1):226–232.

Kinder BW, Collard HR, Koth L, et al. Idiopathic nonspecific interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med. 2007;176(7):691–697.

Kinder BW. Nonspecific interstitial pneumonia. Clin Chest Med. 2012;33(1):111–21.

King CS, Mannem H, Kukreja J, Annam A, Benzaquen S, Dahhan T, et al. Lung transplantation for patients with COVID-19. Chest. 2022;161(1):169–178.

King CS, Nathan SD. Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. Lancet Respir Med. 2017;5:72–84.

King TE Jr, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083-2092.

King TE Jr, Schwarz MI, Brown K, et al. Idiopathic pulmonary fibrosis: relationship between histopathologic features and mortality. Am J Respir Crit Care Med. 2001;164(6):1025–1032.

King TE, Bradford WZ, Castro-Bernardini S, et al. A phase 3 trial of Pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–2092.

Kishi K, Homma S, Kurosaki A, et al. High-resolution computed tomography findings of lung cancer associated with idiopathic pulmonary fibrosis. J Comput Assist Tomogr. 2006;30:95–99.

Kistler KD, Nalysnyk L, Rotella P, et al. Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature. BMC Pulm Med. 2014;14:139.

Kizer JR, Zisman DA, Blumenthal NP, et al. Association between pulmonary fibrosis and coronary artery disease. Arch Intern Med. 2004;164(5):551–556.

Kolb M, Bondue B, Pesci A, et al. Acute exacerbations of progressive-fibrosing interstitial lung diseases. Eur Respir Rev. 2018;27(150):180071.

Kolb M, Vašáková M. The natural history of progressive fibrosing interstitial lung diseases. Respir Res. 2019;20:57.

Kolilekas L, Manali E, Vlami KA, et al. Sleep oxygen desaturation predicts survival in idiopathic pulmonary fibrosis. J Clin Sleep Med. 2013;9:593–601.

Kondoh Y, Azuma A, Inoue Y, et al. Thrombomodulin alfa for acute exacerbation of idiopathic pulmonary fibrosis: a randomized, double-blind placebo-controlled trial. Am J Respir Crit Care Med. 2020;201(9):1110–1119.

Konopka KE, Perry W, Huang T, Farver CF, Myers JL. Usual interstitial pneumonia is the most common finding in surgical lung biopsies following infection with SARS-CoV-2. Clin Med. 2021;42:101209.

Kreuter M, Ehlers-Tenenbaum S, Palmowski K, et al. Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. PLoS One. 2016;11(3):e0151425.

Kreuter M, Ehlers-Tenenbaum S, Palmowski K, et al. Impact of comorbidities on mortality in patients with idiopathic pulmonary fibrosis. PLoS One. 2016;11:e0151425.

Kreuter M, Polke M, Walsh SLF, et al. Acute exacerbation of idiopathic pulmonary fibrosis: international survey and call for harmonisation. Eur Respir J. 2020;55(4):1901760.

Kreuter M, Wuyts W, Renzoni E, et al. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respir Med. 2016;4(5):381–389.

Kreuter M, Wuyts W, Renzoni E, et al. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respir Med. 2016;4:381–389.

Kubo H, Nakayama K, Yanai M, et al. Anticoagulant therapy for idiopathic pulmonary fibrosis. Chest. 2005;128:1475–482.

Kumar A, Cherian SV, Vassallo R, Yi ES, Ryu JH. Current concepts in pathogenesis, diagnosis, and management of smoking-related interstitial lung diseases. Chest. 2018;154(2):394–408.

Kumar P, Goldstraw P, Yamada K, et al. Pulmonary fibrosis and lung cancer: risk and benefit analysis of pulmonary resection. J Thorac Cardiovasc Surg. 2003;125:1321–1327.

Kwee TC, Torigian DA, Alavi A. Nononcological applications of positron emission tomography for evaluation of the thorax. J Thorac Imaging. 2013;28(1):25–39.

Kwon BS, Choe J, Do KH, et al. Computed tomography patterns predict clinical course of idiopathic pulmonary fibrosis. Respir Res. 2020;21:295.

Lama VN, Flaherty KR, Toews GB, Colby TV, Travis WD, Long Q, et al. Prognostic value of desaturation during a six-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med. 2003;168(9):1084–1090.

Lancaster L, Crestani B, Hernandez P, et al. Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. BMJ Open Respir Res. 2019;6:e000397.

Lancaster LH, Mason WR, Parnell JA, et al. Obstructive sleep apnea is common in idiopathic pulmonary fibrosis. Chest. 2009;136:772–778.

Larsen BT, Colby TV. Update for pathologists on idiopathic interstitial pneumonias. Arch Pathol Lab Med. 2012;136(10):1234–1241.

Lavalaye J, Grutters JC, van de Garde EMW, et al. Imaging of fibrogenesis in patients with idiopathic pulmonary fibrosis with cis-4-[18F]-fluoro-L-proline PET. Mol Imaging Biol. 2009;11(2):123–127

Lazar M, Barbu EC, Chitu CE, Tarmure S, Ciobanu AM, Costache C, et al. Interstitial lung fibrosis following COVID-19 pneumonia. Diagnostics (Basel). 2022;12:2028.

Le Jeune I, Gribbin J, West J, et al. The incidence of cancer in patients with idiopathic pulmonary fibrosis and sarcoidosis in the UK. Respir Med. 2007;101(12):2534–2540.

Lederer DJ, Arcasoy SM, Wilt JS, et al. Six-minute-walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174:659–664.

Lederer DJ, Martinez FJ. Idiopathic pulmonary fibrosis. N Engl J Med. 2018;378:1811–1823.

Lee JS, Collard HR, Anstrom KJ, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med. 2013;1:369–376.

Lee JS, Collard HR, Raghu G, et al. Does chronic microaspiration cause idiopathic pulmonary fibrosis? Am J Med. 2010;123(4):304–311.

Lee JS, Ryu JH, Elicker BM, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184:1390–1394.

Lee JS. The role of gastroesophageal reflux and microaspiration in idiopathic pulmonary fibrosis. Clin Pulm Med. 2014;21:81–85.

Lee T, Park JY, Lee HY, et al. Lung cancer in patients with idiopathic pulmonary fibrosis: clinical characteristics and impact on survival. Respir Med. 2014;108:1549-1555.

Lentz RJ, Argento AC, Colby TV, et al. Transbronchial cryobiopsy for diffuse parenchymal lung disease: a state-of-the-art review of procedural techniques, current evidence, and future challenges. J Thorac Dis. 2017;9:2186–2203.

Lettieri CJ, Nathan SD, Barnett SD, et al. Prevalence and outcomes of pulmonary arterial hypertension in advanced idiopathic pulmonary fibrosis. Chest. 2006;129(3):746–752.

Leuchte HH, Neurohr C, Baumgartner R, et al. Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension. Am J Respir Crit Care Med. 2004;170(4):360–365.

Ley B, Bradford WZ, Vittinghoff E, et al. Predictors of mortality poorly predict common measures of disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2016;194(6):711.

Ley B, Bradford WZ, Weycker D, et al. Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis. Eur Respir J. 2015;45(5):1374.

Ley B, Brown KK, Collard HR. Molecular biomarkers in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2014;307:L681–691.

Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(4):431–440.

Ley B, Elicker BM, Hartman TE, et al. Idiopathic pulmonary fibrosis: CT and risk of death. Radiology. 2014;273(2):570–579.

Ley B, Ryerson CJ, Vittinghoff E, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012;156(10):684–691.

Ley B. A glimpse into the future: automated quantitative computed tomography as a biomarker in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2017;195(7):850–852.

LIPinski JH, Moore BB, O’Dwyer DN. The Evolving Role of the Lung Microbiome in Pulmonary Fibrosis. Am J Physiol Lung Cell Mol Physiol. 2020;319(4):L675–682.

Li J, Xia W, Zhan C, Liu S, Yin Z, Wang Z, et al. A telerehabilitation programme in post-discharge COVID-19 patients (TERECO): A randomized controlled trial. Thorax. 2022;77(7):697–706.

Liebow A, Carrington C. The interstitial pneumonias. In: Simon M, Potchen EJ, LeMay M, editors. Frontiers of pulmonary radiology. New York: Grune & Stratton; 1969. p. 102–141.

Lynch DA, Godwin JD, Safrin S, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med. 2005;172(4):488.

Lynch DA, Godwin JD, Safrin S, et al. High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med. 2005;172(4):488–493.

Lynch DA, Sverzellati N, Travis WD, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society white paper. Lancet Respir Med. 2018;6(2):138–153.

Lynch DA, Sverzellati N, Travis WD, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society white paper. Lancet Respir Med. 2018;6:138–53.

Maffessanti M, Dalpiaz G. Diffuse lung diseases: clinical features, pathology, YÇBT. 1st ed. Milan: Springer-Verlag; 2006. p.66–70.

Maher TM, Avram C, Bortey E, et al. Nalbuphine tablets for cough in patients with idiopathic pulmonary fibrosis. NEJM Evidence. 2023;2(8):EVIDoa2300083. doi:10.1056/EVIDoa2300083.

Maher TM, Corte TJ, Fischer A, et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020;8:147–157.

Maher TM, Corte TJ, Fischer A, et al. Ziritaxestat in idiopathic pulmonary fibrosis: results from the randomized, placebo-controlled phase 3 ISABELA 1 and 2 trials. N Engl J Med. 2021;385(10):930–939. doi:10.1056/NEJMoa2108780

Mallick S. Yoğun bakım ünitesinde ventile edilen idiyopatik pulmoner fibrozlu (IPF) hastaların sonuçları. Respir Med. 2008;102(10):1355–1359.

Manali ED, Stathopoulos GT, Kollintza A, et al. The Medical Research Council chronic dyspnea score predicts the survival of patients with idiopathic pulmonary fibrosis. Respir Med. 2008;102(4):586–592.

Mannino DM, Etzel RA, Parrish RG. Pulmonary fibrosis deaths in the United States, 1979–1991: an analysis of multiple-cause mortality data. Am J Respir Crit Care Med. 1996;153:1548–1552.

Martinez F, Chisholm A, Collard HR, et al. The diagnosis of idiopathic pulmonary fibrosis: current and future approaches. Lancet Respir Med. 2017;5:61–71.

Martinez FJ, Collard HR, Pardo A, et al. Idiopathic pulmonary fibrosis. Nat Rev Dis Primers. 2017;3:17074.

Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med. 2005;142(12 Pt 1):963–967.

Martinez FJ, Yow E, Flaherty KR, et al. Effect of antimicrobial therapy on respiratory hospitalization or death in adults with idiopathic pulmonary fibrosis: the CleanUP-IPF randomized clinical trial. JAMA. 2021;325(18):1841–1851.

McCormack FX, King TE Jr, Bucher BL, Nielsen L, Mason RJ. Surfactant protein A predicts survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1995;152(2):751–759.

McDonald LT. Healing after COVID-19: Are survivors at risk for pulmonary fibrosis? Am J Physiol Lung Cell Mol Physiol. 2021;320:L257–265.

Mei G, Liu Z, Zuo H, Yang Z, Qu J. Idiopathic fibrosis: An update on Pathogenesis. Front Pharmacol. 2022;12.

Meissner HH, Soo Hoo GW, Khonsary SA, et al. Idiopathic pulmonary fibrosis: evaluation with positron emission tomography. Respiration. 2006;73(2):197–202.

Mermigkis C, Bouloukaki I, Antoniou K, et al. Obstructive sleep apnea should be treated in patients with idiopathic pulmonary fibrosis. Sleep Breath. 2015;19:385–391.

Mermigkis C, Bouloukaki I, Schiza SE. Sleep as a new target for improving outcomes in idiopathic pulmonary fibrosis. Chest. 2017;152(6):1327–1338.

Mermigkis C, Chapman J, Golish J, et al. Sleep-related breathing disorders in patients with idiopathic pulmonary fibrosis. Lung. 2007;185(3):173–178.

Mermigkis C, Stagaki E, Tryfon S, et al. How common is sleep-disordered breathing in patients with idiopathic pulmonary fibrosis? Sleep Breath. 2010;14(4):387–390.

Mermigkis C, Stagaki E, Tryfon S, et al. How common is sleep-disordered breathing in patients with idiopathic pulmonary fibrosis? Sleep Breath. 2010;14:387–390.

Meyer KC, Raghu G, Baughman RP, et al. An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med. 2012;185(9):1004–1014.

Meyer KC. Acute exacerbations of interstitial lung disease: what is the best treatment? Sarcoidosis Vasc Diffuse Lung Dis. 2021;38(1):e2021001.

Minegishi Y, Sudoh J, Kuribayasi H, et al. The safety and efficacy of weekly paclitaxel in combination with carboplatin for advanced nonsmall cell lung cancer with idiopathic interstitial pneumonias. Lung Cancer. 2011;71:70–74.

Mohammadi A, Balan I, Yadav S, Pearce N, Callaway L, Houghton L, et al. Post-COVID-19 pulmonary fibrosis. Cureus. 2022;14(3):e22770.

Molyneaux PL, Cox MJ, Willis-Owen SA, et al. The role of bacteria in the pathogenesis and progression of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2014;190(8):906–913.

Moore C, Blumhagen RZ, Yang IV, et al. Resequencing Study Confirms that Host Defense and Cell Senescence Gene Variants Contribute to the Risk of Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2019;200(2):199–208.

Moua T, Ryu JH. Recognizing and treating co-morbidities of IPF. In: Meyer KC, Nathan SD, editors. Idiopathic Pulmonary Fibrosis: A Comprehensive Clinical Guide. New York: Springer Science and Business Media; 2013. p. 313–336.

Mura M, Porretta MA, Bargagli E, et al. Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J. 2012;40(1):101.

Musellim B, Mogulkoc N, Uzun O, et al. Evaluation of patients with fibrotic interstitial lung disease: preliminary results from the TURK-UIP study. Turk Thorac J. 2021;22(2):102–109.

Musellim B, Okumus G, Uzaslan E, et al. Epidemiology and distribution of interstitial lung diseases in Turkey. Clin Respir J. 2013;8:55–62.

Myall KJ, Mukherjee B, Castanheira AM, Lam JL, Benedetti G, Mak SM, et al. Persistent post-COVID-19 interstitial lung disease: An observational study of corticosteroid treatment. Ann Am Thorac Soc. 2021;18:799–806.

Myers JL, Katzenstein AL. Epithelial necrosis and alveolar collapse in the pathogenesis of usual interstitial pneumonia. Chest. 1988;94(6):1309–1311.

Myers JL, Veal CF Jr, Shin MS, Katzenstein AL. Respiratory bronchiolitis causing interstitial lung disease. A clinicopathologic study of six cases. Am Rev Respir Dis. 1987;135(4):880–884.

Nabahati M, Ebrahimpour S, Khanleghnejad Tabari R, Mehraeen R. Post-COVID-19 pulmonary fibrosis and its predictive factors: A prospective study. Egypt J Radiol Nucl Med. 2021;52(1):1–7.

Naccache JM, Jouneau S, Didier M, et al. Cyclophosphamide added to glucocorticoids in acute exacerbation of idiopathic pulmonary fibrosis (EXAFIP): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respir Med. 2022;10(1):26–34.

Nadrous HF, Pellikka PA, Krowka MJ, et al. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest. 2005;128(4):2393–2399.

Nalysnyk L, Cid-Rufaza J, Rotella P, Esser D. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev. 2012;21:355–361.

Nathan SD, Albera C, Bradford WZ, et al. Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis. Thorax. 2016;71(5):429-435.

Nathan SD, Barbera JA, Gaine SP, et al. Pulmonary hypertension in chronic lung disease and hypoxia. Eur Respir J. 2019;53(1): 1801914. doi:10.1183/13993003.01914 2018

Nathan SD, Barnett SD, Urban BA, et al. Pulmonary embolism in idiopathic pulmonary fibrosis transplant recipients. Chest. 2003;123(5):1758–1763.

Nathan SD, Costabel U, Albera C, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment. Respir Med. 2019;153:44-51.

Nathan SD, du Bois RM, Albera C, et al. Validation of test performance characteristics and minimal clinically important difference of the 6-minute walk test in patients with idiopathic pulmonary fibrosis. Respir Med. 2015;109(7):914.

Nathan SD, King CS. Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design? Drug Des Devel Ther. 2014;8:875–885.

Nathan SD, Noble PW, Tuder RM. Idiopathic pulmonary fibrosis and pulmonary hypertension: connecting the dots. Am J Respir Crit Care Med. 2007;175(9):875–880.

Nathan SD, Shlobin OA, Ahmad S, et al. Serial development of pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Respiration. 2008;76:288-294.

Nathan SD, Shlobin OA, Barnett SD, Saggar R, Belperio JA, Lynch JP. Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med. 2011;105(4):612–618.

Nathan SD, Shlobin OA, Weir N, et al. Long-term course and prognosis of idiopathic pulmonary fibrosis in the new millennium. Chest. 2011;140(1):221–229.

Natsuizaka M, Chiba H, Kuronuma K, et al. Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences. Am J Respir Crit Care Med. 2014;190(7):773–779.

Navaratnam V, Fleming KM, West J, et al. The rising incidence of idiopathic pulmonary fibrosis in the UK. Thorax. 2011;66:462–467.

Nicholson AG, Addis BJ, Bharucha H, et al. Inter-observer variation between pathologists in diffuse parenchymal lung disease. Thorax. 2004;59(6):500–505.

Nicholson AG, Colby TV, du Bois RM, Hansell DM, Wells AU. The prognostic significance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fibrosing alveolitis. Am J Respir Crit Care Med. 2000;162(6):2213–2217.

Nicholson AG, Fulford LG, Colby TV, et al. The relationship between individual histologic features and disease progression in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2002;166(2):173–177.

Nishiyama O, Kondoh Y, Kimura T, et al. Effects of pulmonary rehabilitation in patients with idiopathic pulmonary fibrosis. Respirology. 2008;13(3):394–399.

Nishiyama O, Taniguchi H, Kondoh Y, et al. A simple assessment of dyspnoea as a prognostic indicator in idiopathic pulmonary fibrosis. Eur Respir J. 2010;36(5):1067–1072.

Noble PW, Albera C, Bradford WZ, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760-1769.

Noble PW, Homer RJ. Back to the future: historical perspective on the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol. 2005;33(2):113–120.

Noth I, Anstrom KJ, Calvert SB, et al. A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012;186:88–95.

Noth I, Zhang Y, Ma SF, et al. Genetic variants associated with idiopathic pulmonary fibrosis susceptibility and mortality: a genome-wide association study. Lancet Respir Med. 2013;1(4):309–317.

Oishi K, Aoe K, Mimura Y, et al. Survival from an acute exacerbation of idiopathic pulmonary fibrosis with or without direct hemoperfusion with a polymyxin B-immobilized fiber column: a retrospective analysis. Intern Med. 2016;55(24):3551–3559.

Oldham JM, Noth I. Idiopathic pulmonary fibrosis: early detection and referral. Respir Med. 2014;108:818–828.

Oliveira DS, Araújo Filho JA, Paiva AFL, et al. Idiopathic interstitial pneumonias: review of the latest American Thoracic Society/European Respiratory Society classification. Radiol Bras. 2018;51(5):321-327.

Olschewski H, Ghofrani HA, Walmrath D, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fibrosis. Am J Respir Crit Care Med. 1999;160(2):600–607.

Olson AL, Swigris JJ, Raghu G, Brown KK. Seasonal variation: mortality from pulmonary fibrosis is greatest in the winter. Chest. 2009;136(1):16–22.

Omori T, Tajiri M, Baba T, et al. Pulmonary resection for lung cancer in patients with idiopathic interstitial pneumonia. Ann Thorac Surg. 2015;100(3):954–960.

Oronsky B, Larson C, Hammond TC, Kesari S, Lybeck M, Caroen S. A review of persistent post-Covid syndrome (PPCS). Clin Rev Allergy Immunol. 2021;20:1–9.

Ozawa Y, Suda T, Naito T, et al. Cumulative incidence of and predictive factors for lung cancer in IPF. Respirology. 2009;14(5):723–728.

Pankratz DG, Choi Y, Imtiaz U, et al. Usual interstitial pneumonia can be detected in transbronchial biopsies using machine learning. Ann Am Thorac Soc. 2017;14:1646–1654.

Panos RJ, Mortenson RL, Niccoli SA, King TE Jr. Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med. 1990;88(4):396–404.

Papadopoulos CE, Pitsiou G, Karamitsos TD, et al. Left ventricular diastolic dysfunction in idiopathic pulmonary fibrosis: a tissue doppler echocardiographic [corrected] study. Eur Respir J. 2008;31(4):701–706.

Pardo A, Selman M. The Interplay of the Genetic Architecture, Aging, and Environmental Factors in the Pathogenesis of Idiopathic Pulmonary Fibrosis. Am J Respir Cell Mol Biol. 2021;64:163–172.

Patti MG, Tedesco P, Golden J, et al. Idiopathic pulmonary fibrosis: how often is it really idiopathic? J Gastrointest Surg. 2005;9(8):1053-1056.

Pedraza-Serrano F, Jimenez-Garcia R, Lopez-de-Andres A, et al. Comorbidities and risk of mortality among hospitalized patients with idiopathic pulmonary fibrosis in Spain from 2002 to 2014. Respir Med. 2018;138:137–143.

Peljto AL, Zhang Y, Fingerlin TE, et al. Association between the MUC5B promoter polymorphism and survival in patients with idiopathic pulmonary fibrosis. JAMA. 2013;309:2232–2239.

Petnak T, Lertjitbanjong P, Thongprayoon C, Moua T. Impact of antifibrotic therapy on mortality and acute exacerbation in idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Chest. 2021;160(5):1751–1763.

Pezzuto G, Claroni G, Puxeddu E, et al. Structured multidisciplinary discussion of YÇBT scans for IPF/UIP diagnosis may result in indefinite outcomes. Sarcoidosis Vasc Diffuse Lung Dis. 2015;32:32.

Pıhtılı A, Bingol Z, Kıyan E, et al. Obstructive sleep apnea is common in patients with interstitial lung disease. Sleep Breath. 2013;17:1281–1288.

Piñeiro-Hermida S, Autilio C, Martínez P, et al. Telomerase Treatment Prevents Lung Profibrotic Pathologies Associated with Physiological Aging. J Cell Biol. 2020;219(10):e202002120.

Podolanczuk AJ, Kim JS, Cooper CB, et al. Design and rationale for the prospective treatment efficacy in IPF using genotype for NAC selection (PRECISIONS) clinical trial. BMC Pulm Med. 2022 Dec 13;22(1):475. doi:10.1186/s12890-022-02281-8.

Podolanczuk AJ, Oelsner EC, Barr RG, et al. High attenuation areas on chest computed tomography in community-dwelling adults: the MESA study. Eur Respir J. 2016;48(5):1442–1452.

Prasse A, Probst C, Bargagli E, et al. Serum CC-chemokine ligand 18 concentration predicts outcome in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2009;179(8):717–723.

Putman RK, Gudmundsson G, Axelsson GT, et al. Imaging patterns are associated with interstitial lung abnormality progression and mortality. Am J Respir Crit Care Med. 2019;200:175–183.

Putman RK, Hatabu H, Araki T, et al. Association between interstitial lung abnormalities and all-cause mortality. JAMA. 2016;315(7):672–681.

Quadrelli S, Molinari L, Ciallella L, et al. Radiological versus histopathological diagnosis of usual interstitial pneumonia in the clinical practice: does it have any survival difference? Respiration. 2010;79(1):32-37.

Raghu G, Amatto VC, Behr J, et al. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J. 2015;46(4):1113–1130.

Raghu G, Amatto VC, Behr J, Stowasser S. Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. Eur Respir J. 2015;46:1113–1130.

Raghu G, Collard HR, Egan J, et al. An Official ATS/ERS/ JRS/ALAT Statement: Idiopathic Pulmonary Fibrosis: Evidence-based Guidelines for Diagnosis and Management. Am J Respir Crit Care Med. 2011;183:788-824.

Raghu G, Collard HR, Egan J, et al. An official ATS/ERS/JRS/ALAT statement: Idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788–824.

Raghu G, Crestani B, Bailes Z, et al. Effect of anti-acid medication on reduction in FVC decline with nintedanib. Eur Respir J. 2015;46:A4502.

Raghu G, Flaherty KR, Lederer DJ, et al. Use of a molecular classifier to identify usual interstitial pneumonia in conventional transbronchial lung biopsy samples: a prospective validation study. Lancet Respir Med. 2019;7:487–496.

Raghu G, Remy-Jardin M, Myers J, et al. The 2018 diagnosis of idiopathic pulmonary fibrosis guidelines: surgical lung biopsy for radiological pattern of probable usual interstitial pneumonia is not mandatory. Am J Respir Crit Care Med. 2019;200:1089–1092.

Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44–e68.

Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198(5):e44–e68.

Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44–e68.

Raghu G, Remy-Jardin M, Myers JL, et al. The 2018 diagnosis of idiopathic pulmonary fibrosis guidelines: surgical lung biopsy for radiological pattern of probable usual interstitial pneumonia is not mandatory. Am J Respir Crit Care Med. 2019;200:1089–1092.

Raghu G, Remy-Jardin M, Myers JL, et al; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of idiopathic pulmonary fibrosis: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2018;198:e44–e68.

Raghu G, Remy-Jardin M, Richeldi L, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205(9):e18–e47. doi:10.1164/rccm.202202-0399ST

Raghu G, Rochwerg B, Zhang Y, et al. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. Am J Respir Crit Care Med. 2015;192(2):e3–19.

Raghu G, van den Blink B, Hamblin MJ, et al. Effect of recombinant human pentraxin 2 vs placebo on change in forced vital capacity in patients with idiopathic pulmonary fibrosis: a randomized clinical trial. JAMA. 2021;326(4):370–379. doi:10.1001/jama.2021.11095

Raghu G, Wells AU, Nicholson AG, et al. Effect of nintedanib in subgroups of idiopathic pulmonary fibrosis by diagnostic criteria. Am J Respir Crit Care Med. 2017;195:78–85.

Raghu G, Weycker D, Edelsberg J, et al. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174(7):810-816.

Raghu G, Yang ST, Spada C, et al. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest. 2006;129:794–800.

Raghu G. Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years. Eur Respir J. 2017;50:1701209.

Raghunath S, Rajagopalan S, Karwoski RA, et al. Quantitative stratification of diffuse parenchymal lung diseases. PLoS One. 2014;9(3):e93229.

Rahaghi FF, Safdar Z, Brown AW, et al. Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study. BMC Pulm Med. 2020;20(1):191.

Redente EF, Jacobsen KM, Solomon JJ, et al. Age and sex dimorphisms contribute to the severity of bleomycin-induced lung injury and fibrosis. Am J Physiol Lung Cell Mol Physiol. 2011;301(4):L510–L518.

Richeldi L, Azuma A, Cottin V, et al. Trial of a preferential phosphodiesterase 4B inhibitor for idiopathic pulmonary fibrosis. N Engl J Med. 2022 Jun 9;386(23):2178 2187. doi:10.1056/NEJMoa2201737.

Richeldi L, Collard HR, Jones MG. Idiopathic Pulmonary Fibrosis. Lancet. 2017;389:1941–1952.

Richeldi L, Costabel U, Selman M, et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med. 2011;365:1079-1087.

Richeldi L, Crestani B, Azuma A, et al. Outcomes following decline in forced vital capacity in patients with idiopathic pulmonary fibrosis: results from the INPULSIS and INPULSIS-ON trials of nintedanib. Respir Med. 2019;156:20-25.

Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-82. Erratum in: N Engl J Med. 2015;373(8):782.

Richeldi L, du Bois RM, Raghu G, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071-2082.

Richeldi L, Fernández Pérez ER, Costabel U, et al. Pamrevlumab, an anti–connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2020;8(1):25–33. doi:10.1016/S2213-2600(19)30262-0

Richeldi L, Kolb M, Azuma A, et al. Efficacy and safety of nintedanib plus sildenafil in patients with idiopathic pulmonary fibrosis and severe impairment in gas exchange (INSTAGE): a randomised, double-blind, placebo-controlled, phase 3 trial. N Engl J Med. 2018;379(18):1722-1731.

Richeldi L, Scholand MB, Lynch DA, et al. Utility of a molecular classifier as a complement to high-resolution computed tomography to identify usual interstitial pneumonia. Am J Respir Crit Care Med. 2021;203:211–220.

Romagnoli M, Nannini C, Piciucchi S, et al. Idiopathic nonspecific interstitial pneumonia: an interstitial lung disease associated with autoimmune disorders? Eur Respir J. 2011;38(2):384–391.

Romei C, Turturici L, Tavanti L, et al. The use of chest magnetic resonance imaging in interstitial lung disease: a systematic review. Eur Respir Rev. 2018;27(150):180061.

Rubin EH, Lubliner R. The Hamman-Rich syndrome: review of the literature and analysis of 15 cases. Medicine (Baltimore). 1957;36(4):397–463.

Ruocco G, Cekorja B, Rottoli P, et al. Role of BNP and echo measurement for pulmonary hypertension recognition in patients with interstitial lung disease: an algorithm application model. Respir Med. 2015;109(3):406–415.

Ryerson CJ, Arean PA, Berkeley J, et al. Depression is a common and chronic comorbidity in patients with interstitial lung disease. Respirology. 2012;17:525–532.

Ryerson CJ, Berkeley J, Carrieri-Kohlman VL, et al. Depression and functional status are strongly associated with dyspnea in interstitial lung disease. Chest. 2011;139:609–616.

Ryerson CJ, Cayou C, Topp F, et al. Pulmonary rehabilitation improves long-term outcomes in interstitial lung disease: a prospective cohort study. Respir Med. 2014;108:203–210.

Ryerson CJ, Cottin V, Brown KK, Collard HR. Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm. Eur Respir J. 2015;46(2):512–520.

Ryerson CJ, Hartman T, Elicker BM, et al. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest. 2013;144:234-240.

Ryu JH. Chemotherapy-induced pulmonary toxicity in lung cancer patients. J Thorac Oncol. 2010;5(9):1313–1314.

Sakamoto S, Shimizu H, Isshiki T, et al. New risk scoring system for predicting 3-month mortality after acute exacerbation of idiopathic pulmonary fibrosis. Sci Rep. 2022;12:1134.

Salisbury ML, Myers JL, Belloli EA, et al. Diagnosis and treatment of fibrotic hypersensitivity pneumonia: where we stand and where we need to go. Am J Respir Crit Care Med. 2017;196(6):690–699.

Salisbury ML, Tolle LB, Xia M, et al. Possible UIP pattern on high-resolution computed tomography is associated with better survival than definite UIP in IPF patients. Respir Med. 2017;131:229–235.

Savarino E, Carbone R, Marabotto E, et al. Gastro-oesophageal reflux and gastric aspiration in idiopathic pulmonary fibrosis patients. Eur Respir J. 2013;42:1322–1331.

Scadding JG. Fibrosing alveolitis. Br Med J. 1964;2(5410):686.

Schuhmann M, Brims FJ, O’Reilly KM. Asbestos-related lung disease: an update. Clin Pulm Med. 2011;18(6):265–273.

Schwartz DA. Idiopathic pulmonary fibrosis is a complex genetic disorder. Trans Am Clin Clim Assoc. 2016;127:34–45.

Seibold MA, Wise AL, Speer MC, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011;364(16):1503–1512.

Seifirad S. Pirfenidone: A novel hypothetical treatment for COVID-19. Med Hypotheses. 2020;144:110005.

Sellares J, Hernandez-Gonzalez V, Lucena C, et al. Auscultation of velcro crackles is associated with usual interstitial pneumonia. Medicine (Baltimore). 2016;95(5):e2573.

Selman M, Martinez FJ, Pardo A. Why Does an Aging Smoker’s Lung Develop Idiopathic Pulmonary Fibrosis and Not Chronic Obstructive Pulmonary Disease? Am J Respir Crit Care Med. 2019;199(3):279–285.

Sgalla G, Iovene B, Calvello M, et al. Idiopathic pulmonary fibrosis: pathogenesis and management. Respir Res. 2018;19:32–50.

Shah W, Hillman T, Playford ED, Hishmeh L. Managing the long-term effects of COVID-19: summary of NICE, SIGN and RCGP rapid guideline. BMJ. 2021;372:n136. doi:10.1136/bmj.n136.

Sheridan LA, Harrison EG Jr, Divertie MB. The current status of idiopathic pulmonary fibrosis (Hamman-Rich Syndrome). Med Clin North Am. 1964;48:993–1010.

Sherner J, Collen J, King CS, Nathan SD. Pulmonary hypertension in idiopathic pulmonary fibrosis: epidemiology, diagnosis, and therapeutic implications. Curr Respir Care Rep. 2012;1:233–242.

Shlobin OA, Brown AW, Nathan SD. Pulmonary hypertension in diffuse parenchymal lung diseases. Chest. 2017;151(1):204–214.

Shorr AF, Wainright JL, Cors CS, et al. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J. 2007;30(4):715–721.

Shorr AF, Wainright JL, Cors CS, et al. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J. 2007;30:715-721.

Shumar JN, Chandel A, King CS. Antifibrotic therapies and progressive fibrosing interstitial lung disease (PF-ILD): building on INBUILD. J Clin Med. 2021;10(11):2285.

Song JW, Hong SB, Lim CM, et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J. 2011;37(2):356–363.

Søyseth V, Aaløkken TM, Mynarek G, et al. Diagnosis of biopsy-verified usual interstitial pneumonia by computed tomography. Respir Med. 2015;109(7):897-903.

Spagnolo P, Wuyts W. Acute exacerbations of interstitial lung disease: lessons from idiopathic pulmonary fibrosis. Curr Opin Pulm Med. 2017;23(5):411–417.

Sprunger DB, Olson AL, Huie TJ, et al. Pulmonary fibrosis is associated with an elevated risk of thromboembolic disease. Eur Respir J. 2012;39:125–132.

Strongman H, Kausar I, Maher TM. Incidence, prevalence, and survival of patients with idiopathic pulmonary fibrosis in the UK. Adv Ther. 2018;35(5):724–736.

Stuart BD, Lee JS, Kozlitina J, et al. Effect of telomere length on survival in patients with idiopathic pulmonary fibrosis: an observational cohort study with independent validation. Lancet Respir Med. 2014;2(7):557–655.

Sumikawa H, Johkoh T, Colby TV, et al. Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival. Am J Respir Crit Care Med. 2008;177(4):433-439.

Suzuki A, Kondoh Y. The clinical impact of major comorbidities on idiopathic pulmonary fibrosis. Respir Investig. 2017;55:94-103.

Swigris JJ, Fairclough DL, Morrison M, et al. Benefits of pulmonary rehabilitation in idiopathic pulmonary fibrosis. Respir Care. 2011;56(6):783–789.

Takeda A, Enomoto T, Sanuki N, et al. Acute exacerbation of subclinical idiopathic pulmonary fibrosis triggered by hypofractionated stereotactic body radiotherapy in a patient with primary lung cancer and slightly focal honeycombing. Radiat Med. 2008;26:504–507.

Tang YW, Johnson JE, Browning PJ, et al. Herpes virus DNA is consistently detected in lungs of patients with idiopathic pulmonary fibrosis. J Clin Microbiol. 2003;41:2633–2640.

Tanizawa K, Collard HR, Ryerson CJ. IPF: definition, severity and impact of pulmonary exacerbations. In: Burgel PR, Contoli M, López-Campos JL, eds. Acute Exacerbations of Pulmonary Diseases. Sheffield: European Respiratory Society; 2017:58–65.

Teramachi R, Kondoh Y, Kataoka K, et al. Outcomes with newly proposed classification of acute respiratory deterioration in idiopathic pulmonary fibrosis. Respir Med. 2018;143:147–152.

Thachil J, Lisman T. Pulmonary megakaryocytes in coronavirus disease 2019 (COVID-19): Roles in thrombi and fibrosis. Semin Thromb Hemost. 2020;46:831–834.

The RECOVERY Collaborative Group. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): A randomized, controlled, open-label, platform trial. Lancet. 2021;397:605–612.

The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19. N Engl J Med. 2021;384:693–704.

Thomeer M, Demedts M, Vandeurzen K. Registration of interstitial lung diseases by 20 centres of respiratory medicine in Flanders. Acta Clin Belg. 2001;56:163–172.

Tomassetti S, Gurioli C, Ryu JH, et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest. 2015;147(1):157–164.

Tomassetti S, Gurioli C, Ryu JH, et al. The impact of lung cancer on survival of idiopathic pulmonary fibrosis. Chest. 2015;147:157–164.

Tomassetti S, Ryu JH, Poletti V. Staging systems and disease severity assessment in interstitial lung diseases. Curr Opin Pulm Med. 2015;21(5):463–469.

Tomassetti S, Wells AU, Costabel U, et al. Bronchoscopic lung cryobiopsy increases diagnostic confidence in the multidisciplinary diagnosis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2016;193:745.

Torrisi SE, Ley B, Kreuter M, et al. The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study. Eur Respir J. 2019;53(3): 1801587. doi:10.1183/13993003.01587 2018.

Torrisi SE, Ley B, Kreuter M, et al. The added value of comorbidities in predicting survival in idiopathic pulmonary fibrosis: a multicentre observational study. Eur Respir J. 2019;53(3): 1801587. doi:10.1183/13993003.01587-2018.

Torrisi SE, Pavone M, Vancheri A, Vancheri C. When to start and when to stop antifibrotic therapies. Eur Respir Rev. 2017;26(145):170053.

Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188:733–748.

Travis WD, Costabel U, Hansell DM, et al. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733–48.

Troy LK, Corte TJ. Sleep disordered breathing in interstitial lung disease: a review. World J Clin Cases. 2014;2:828–834.

Troy LK, Grainge C, Corte TJ, et al. Diagnostic accuracy of transbronchial lung cryobiopsy for interstitial lung disease diagnosis (COLDICE): a prospective, comparative study. Lancet Respir Med. 2020;8:171–181.

Türk Toraks Derneği. İdiyopatik Pulmoner Fibrozis Tanı ve Tedavi Uzlaşı Raporu. Ankara: Bilimsel Tıp Yayınevi; 2018 p. 69 72.

Türk Toraks Derneği. İdiyopatik Pulmoner Fibrozis Tanı ve Tedavi Uzlaşı Raporu. Ankara: Türk Toraks Derneği Yayınları; 2018. s. 217–218.

Udwadia ZF, Koul PA, Richeldi L. Post-COVID lung fibrosis: The tsunami that will follow the earthquake. Lung India. 2021;38(Suppl):S41–47.

Umemura Y, Mitsuyama Y, Minami K, Tanaka T, Inomata M, Nishida T, et al. Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study. Int J Infect Dis. 2021;108:454–460.

United Therapeutics Corporation. A study of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis (TETON-1 and TETON-2). ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US); 2021 Jan 14 [cited 2025 Aug 1]. Available from: https://clinicaltrials.gov/ct2/show/NCT04708782

Vadasz I, Husain-Syed F, Dorfmuller P, Roller FC, Heukamp L, Mayer K, et al. Severe organizing pneumonia following COVID-19. Thorax. 2021;76(2):201–204.

Vainshelboim B, Oliveira J, Yehoshua L, et al. Exercise training-based pulmonary rehabilitation program is clinically beneficial for idiopathic pulmonary fibrosis. Respiration. 2014;88(5):378–388.

Valeyre D, Albera C, Bradford WZ, et al. Comprehensive assessment of the long-term safety of pirfenidone in patients with idiopathic pulmonary fibrosis. Respirology. 2014;19(5):740-747.

van Beek EJR, Hoffman EA. Functional imaging: CT and MRI. Clin Chest Med. 2008;29(1):195–216.

van Manen MJ, Birring SS, Vancheri C, et al. Cough in idiopathic pulmonary fibrosis. Eur Respir Rev. 2016;25(141):278–286.

van Manen MJG, Vermeer LC, Moor CC, et al. Clubbing in patients with fibrotic interstitial lung diseases. Respir Med. 2017;132:226–231.

Vancheri C, Failla M, Crimi N, Raghu G. Idiopathic pulmonary fibrosis: a disease with similarities and links to cancer biology. Eur Respir J. 2010;35:496–504.

Vancheri C, Kreuter M, Richeldi L, et al. Nintedanib with add-on pirfenidone in idiopathic pulmonary fibrosis: results of the INJOURNEY trial. Am J Respir Crit Care Med. 2018;197(3):356-363.

Vassallo R, Ryu JH. Smoking-related interstitial lung diseases. Clin Chest Med. 2012;33(1):165–178.

Vigeland CL, Hughes AH, Horton MR. Etiology and treatment of cough in idiopathic pulmonary fibrosis. Respir Med. 2017;123:98–104.

Walsh SLF. Imaging biomarkers and staging in IPF. Curr Opin Pulm Med. 2018;24(5):445–452.

Watanabe A, Miyajima M, Mishina T, et al. Surgical treatment for primary lung cancer combined with idiopathic pulmonary fibrosis. Gen Thorac Cardiovasc Surg. 2013;61:254–261.

Watanabe Y, Kawabata Y, Koyama N, et al. A clinicopathological study of surgically resected lung cancer in patients with usual interstitial pneumonia. Respir Med. 2017;129:158–163.

Waxman A, Restrepo-Jaramillo R, Thenappan T, et al. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med. 2021;384:325–334.

Waxman AB, Restrepo-Jaramillo R, Thenappan T, et al. Inhaled treprostinil in pulmonary hypertension due to interstitial lung disease. N Engl J Med. 2021;384(4):325–334. doi:10.1056/NEJMoa2008470

Weill D, Benden C, Corris PA, Dark JH, Davis RD, Keshavjee S, et al. A consensus document for the selection of lung transplant candidates: 2014—an update from the Pulmonary Transplantation Council of the ISHLT. J Heart Lung Transplant. 2015;34(1):1–15.

Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014—an update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant. 2015;34:1–15.

Wells AU, Brown KK, Flaherty KR, Kolb M, Thannickal VJ. What’s in a name? That which we call IPF, by any other name would act the same. Eur Respir J. 2018;51(5):1801003.

Wells AU, Flaherty KR, Brown KK, et al; INBUILD Trial Investigators. Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. Lancet Respir Med. 2020;8:453–460.

Wells AU, Hirani N; British Thoracic Society Interstitial Lung Disease Guideline Group. Interstitial lung disease guideline. Thorax. 2008;635):1–58.

Wells AU. Managing diagnostic procedures in idiopathic pulmonary fibrosis. Eur Respir Rev. 2013;22(128):158-162.

Wiertz IA, Wuyts WA, Van Moorsel CHM, et al. Unfavourable outcome of glucocorticoid treatment in suspected idiopathic pulmonary fibrosis. Respirology. 2018;23(3):311-317.

Wijsenbeek M, Kreuter M, Olson A, et al. Progressive fibrosing interstitial lung diseases: current practice in diagnosis and management. Curr Med Res Opin. 2019;35(11):2015–2024.

Wijsenbeek M, Suzuki A, Maher T. Interstitial lung disease. Lancet. 2022;400:769–786.

Wolters PJ, Blackwell TS, Eickelberg O, et al. Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic? Lancet Respir Med. 2018;6(2):154–160.

Wong AW, Ryerson CJ, Guler SA. Progression of fibrosing interstitial lung disease. Respir Res. 2020;21(1):32.

World Health Organization (WHO). Coronavirus disease (COVID-19) pandemic [Internet]. Geneva: World Health Organization; [cited 2025 Aug 1]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019

Yagi M, Taniguchi H, Kondoh Y, et al. CT-determined pulmonary artery to aorta ratio as a predictor of elevated pulmonary artery pressure and survival in idiopathic pulmonary fibrosis. Respirology. 2017;22(7):1393–1399.

Ye Q, Huang K, Ding Y, et al. Cigarette smoking contributes to idiopathic pulmonary fibrosis associated with emphysema. Chin Med J (Engl). 2014;127:469–474.

Yu M, Liu Y, Xu D, Zhang R, Lan L, Xu H, et al. Prediction of the development of pulmonary fibrosis using serial thin-section CT and clinical features in patients discharged after treatment for COVID-19 pneumonia. Korean J Radiol. 2020;21:746–755.

Zaman T, Lee JS. Risk factors for the development of idiopathic pulmonary fibrosis: a review. Curr Pulmonol Rep. 2018;7(4):118–125.

Zaman T, Moua T, Vittinghoff E, et al. Differences in clinical characteristics and outcomes between men and women with idiopathic pulmonary fibrosis: a multicenter retrospective cohort study. Chest. 2020;158(1):245–251.

Zang C, Zheng Y, Wang Y, Li L. The effects and safety of pirfenidone in the treatment of idiopathic pulmonary fibrosis: a meta-analysis and systematic review. Eur J Med Res. 2021;26(1):129.

Zhang F, Wei Y, He L, Wang H, Zhao Y, Zhang X, et al. A trial of pirfenidone in hospitalized adult patients with severe coronavirus disease 2019. Chin Med J (Engl). 2022;135:368–370.

Zisman DA, Kawut SM. Idiopathic pulmonary fibrosis: a shot through the heart? Am J Respir Crit Care Med. 2008;178:1192–1193.

Zisman DA, Ross DJ, Belperio JA, et al. Prediction of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med. 2007;101:2153-2159.

Zisman DA, Schwarz MI, Anstrom KJ, et al. A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis. N Engl J Med. 2010;363(7):620–628.

Zou JN, Sun L, Wang BR, Zou Y, Xu S, Ding YJ, et al. The characteristics and evolution of pulmonary fibrosis in COVID-19 patients as assessed by AI-assisted chest YÇBT. PLoS One. 2021;16(3):e0248957.